Background: Non-motor symptoms are common in Parkinson's disease (PD) and can even be used as part of the supportive criteria for diagnosis. Chronic inflammation is involved in every stage of PD. Disorders of the immune system affect the peripheral blood. Whether the humoral immune response is associated with the non-motor symptoms of PD remains unknown.
INTRODUCTION
Parkinson's disease (PD) is a common neurodegenerative disease characterized by alpha-synuclein (α-syn) deposition and a loss of dopaminergic neurons in the substantia nigra (SN) (Rocha et al., 2018) . Apart from the cardinal motor manifestations, non-motor symptoms (NMSs) can also be seen in over 50% of PD patients (Durcan et al., 2019) . Although the underlying mechanism remains elusive, neuroinflammation is considered to be involved in α-syn transmission and dopaminergic neuronal degeneration (Hirsch and Hunot, 2009; Butkovich et al., 2018) .
Disorders of the immune system affect not only the central nervous system but also the humoral immune response in the peripheral blood (Boyko et al., 2017) . Inflammatory cytokines, such as IL-1β, IL-2, IL-6, TNF-α, and IFN-γ, are altered in the sera of patients with PD (Gelders et al., 2018; Yilmaz et al., 2018) . Several of these indicators were reported to be associated with NMSs (Lindqvist et al., 2012; Pereira et al., 2016; Kim et al., 2018) . However, few studies have explored the role of immunoglobulins and the complement system in PD.
The immunoglobulins are important components of humoral immunity (Manz et al., 2005) and mainly consisting of IgG, IgA, and IgM, which can specifically bind antigens and activate complement components (Dunkelberger and Song, 2010) . In the sera of untreated patients with PD, the levels of IgA and IgM are significantly decreased compared to those of patients treated with levodopa (Fiszer et al., 1991) . Consistent with this, among the peripheral blood mononuclear cells, the amount of those secreting immunoglobulins was also found to be decreased in PD patients (Marttila et al., 1985) . Moreover, in parkinsonismdementia disease among Guamanian populations, serum levels of IgA were higher and those of IgM were lower than those in healthy controls (Hoffman et al., 1981) . In addition, increased complement activation has been reported in the SN and serum of PD patients (Bonifati and Kishore, 2007; Orsini et al., 2014) .
Non-motor symptoms seriously affect the quality life of PD patients. Among them, fatigue and depressive symptoms might be influenced by inflammatory mechanisms (Lindqvist et al., 2012) . At present, studies on the inflammatory biomarkers in the peripheral blood of PD patients mainly focus on proinflammatory cytokines (Gelders et al., 2018) . It remains unclear whether immunoglobulins and the complement system contribute to NMSs. In this case-control study, we compared the levels of immunoglobulins (IgG, IgA, and IgM) and complement system components (C3 and C4) between PD patients and healthy controls. We also assessed the relationship between these five indicators and NMSs of patients.
MATERIALS AND METHODS

PD Patients
This study was approved by the Ethics Committee of Qilu Hospital of Shandong University.
Inclusion criteria: patients with Parkinsonian symptoms who met the United Kingdom Brain Bank clinical criteria for PD. Exclusion criteria: (i) patients with a history of regular smoking or alcoholism; (ii) patients with cardiovascular and cerebrovascular disease or hypertension or diabetes complications; (iii) patients with a history of autoimmune disease (involving any of the following systems: thyroid, digestive, kidney, skin, blood and connective tissue); or (iv) patients with acute/chronic infections. In total, 180 sporadic PD patients and 189 healthy controls from the neurology clinic and physical examination center of Qilu Hospital took part in this study with prior and informed consent from 2018 to 2019. According to the Movement Disorders Society (MDS) clinical diagnostic criteria , 62 patients were diagnosed with clinically established PD, while 118 patients were diagnosed with clinically probable PD. The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)-III and the Non-Motor Symptoms Scale (NMSS) were used to assess patient's movement disorder and NMSs, respectively. Anti-parkinsonian drugs were administered at a total daily levodopa equivalent dose (LED). To prevent fluctuations in the scores of MDS-UPDRS-III, patients with on/off fluctuations were not included in this study. The basic information and clinical features of the participants are presented in Table 1 .
Humoral Immunity Indexes
Three milliliters of venous blood was collected in a serum separation hose from the right elbow of each patient between 08:00 am and 10:00 am. After centrifugation, the contents of serum IgG ( 
Statistical Analysis
The levels of serum IgG, IgA, IgM, C3, and C4 were compared between PD patients and healthy controls with the Mann-Whitney test and stratification analysis. The levels of IgG, IgA, IgM, C3, and C4 in patients with different clinical features, including gender (female/male), onset age (≤45 years/>45 years) (Rana et al., 2012) , MDS-UPDRS-III scores (≤32/>33) (Martínez-Martín et al., 2015) , diagnostic certainty (clinically established/probable PD), and LED (<600/≥600 mg/day) (Brooks, 2008) , with or without symptoms in the nine domains of the NMSS, were compared with the Mann-Whitney test. Data are expressed as the median (interquartile range). SPSS 12.0 software (Chicago, IL, United States) was used for the statistical analyses. Bonferroni-adjusted p values (Pc) were used to avoid alpha inflation, and Pc < 0.01 and Pc < 0.004 were regarded as statistically significant. Multiple regression models were used to assess the association between indicators of humoral immunity and the clinical features of PD patients. p < 0.05 was regarded as statistically significant.
RESULTS
The Levels of IgG, IgA, IgM, C3, and C4 Were Similar Between PD Patients and Healthy Controls
The average serum levels of IgG, IgA, IgM, C3, and C4 in patients with PD and healthy controls were all in the normal range. According to the Mann-Whitney test, no significant difference was found among the five indicators between PD patients and healthy controls (p > 0.05) ( Supplementary Table 1 ). 05 (0.65) , p = 0.009] and C3 [0.92 (0.23) vs. 0.96 (0.26), p = 0.021], respectively ( Supplementary Table 2 ).
However, after Bonferroni correction, only patients suffering from attention/memory problems had significantly lower levels of IgA and C3 than those without these problems [1.92 (1.21) vs. 2.57 (0.76); 0.89 (0.24) vs. 0.97 (0.24), Pc < 0.004, respectively, Figure 2] .
These results indicated that the humoral immune response of patients with PD was affected by gender, MDS-UPDRS-III scores, LED, and problems in different NMSS domains.
The Association Between the Five Indicators and the NMSs
To explore the association between the five indicators of humoral immunity and clinical features, multiple regression models involving several factors (gender, age, diagnosis certainty, the course of disease, MDS-UPDRS III score, scores of the nine domains of NMS scale, and LED) were applied in the study. We found that the serum level of IgG was negatively associated with the score of mood/cognition problems (correlation coefficient = −0.209, 95% confidence intervals: −0.408 to −0.010, p = 0.039) and was positively associated with the score of gastrointestinal tract problems (correlation coefficient = 0.312, 95% confidence intervals: 0.083 to 0.542, p = 0.008) (adjusted R 2 = 0.063, F = 1.805, p = 0.038). The serum level of C3 was negatively associated with being a male patient (correlation coefficient = −0.100, 95% confidence intervals: −0.159 to −0.041, p = 0.001), age (correlation coefficient = −0.003, 95% confidence intervals: −0.006 to 0.000, p = 0.007) and the score of sleep/fatigue problems (correlation coefficient = −0.017, 95% confidence intervals: −0.030 to −0.003, p = 0.017) (adjusted R 2 = 0.123, F = 2.678, p = 0.001).
DISCUSSION
Here, a study involving 369 participants was performed to determine the relationship between serum levels of IgG, IgA, IgM, C3, and C4 and the NMSs of PD. We conducted a casecontrol study and correlation analyses and found that male PD patients had obviously lower serum C3 levels than male healthy controls and female PD patients. Serum IgG and C3 were correlated with the NMSs of PD.
The incidence of NMSs is high and is associated with a broad range of deficits (Seppi et al., 2019) . Sleep disorders and gastrointestinal tract problems are common at the prodromal stage of PD and precede the manifestation of motor symptoms (Gjerstad et al., 2018; Pfeiffer, 2018; Galbiati et al., 2019) . Consistent with previous studies, we found that over 50% of patients presented with symptoms in one of the following areas: sleep/fatigue, mood/cognition, attention/memory, gastrointestinal tract, and miscellaneous. Patients with or without NMSs showed different humoral immune responses in terms of serum levels of IgA, IgM, C3, and C4. This implied that humoral immune responses may play a role in the development of NMSs.
Humoral immune responses are influenced by numerous factors. Gaya C. found that the levels of C3 in females were lower than those in males in a healthy Caucasian population (Gaya da Costa et al., 2018) . In contrast, Yang X. reported that there was no significant difference in serum C3 levels between females and males in a Chinese Han population (Yang et al., 2018) . Similarly, we found no obvious differences in serum C3 levels in healthy controls between genders. However, female patients had higher serum levels of C3 and C4 than male patients. Interestingly, after Bonferroni correction, the serum level of C3 remained higher in female than in male patients. C3 is an important component of the complement system, and its activation is involved in the pathogenesis of PD (McGeer et al., 2017) . The absence of C3 in mice did not protect against the depletion of dopaminergic neurons in the toxin-induced MPTP model (Liang et al., 2007) . Traditionally, being female is considered a low risk factor for PD Picillo et al., 2017) . However, females are more likely to suffer from cognitive disorders, pain symptoms, and depression (Georgiev et al., 2017) . PD patients who had higher levels of serum C3 and C4 at baseline and maintained consistently high levels over 2 years had a worse quality of life and memory ability (Veselı et al., 2018) . After adjusting for other clinical factors, we found that the serum C3 level was inversely correlated with male gender, age, and the severity of sleep/fatigue problems. The levels of C3 were higher in the sleep-deprived human (Hui et al., 2007) . Compared to the SLE patients with normal levels of C3, patients with lower C3 had higher FACIT fatigue scale (Li et al., 2017) . We speculate that the complement system might be related to the heterogeneity of NMSs in female patients.
IgG autoantibodies of human serum are abundant, with the profiles strongly influenced by age, gender, and specific diseases (Nagele et al., 2013) . It has been indicated that IgG is intensely immunolabeled with α-syn in the SN neurons of patients with PD (Orr et al., 2013) . No significant difference in the level of serum IgG was found between the healthy controls and PD patients in our study. However, after adjusting for the influence of various confounding factors (gender, age, motor symptoms, NMSs, and doses of levodopa) in the multiple linear regression analysis model, we found that serum IgG levels were negatively associated with mood/cognition problems and were positively associated with gastrointestinal tract dysfunction in PD patients. In patients with generalized anxiety disorder or major depression, the level of serum IgG remained normal (Gold et al., 2012; Islam et al., 2014) . Thus, we hypothesized that the pathological changes of PD might contribute to this. In addition, dopamine levels in the putamen and caudate nucleus were negatively correlated with serum IgG in PD patients with constipation (Zhou et al., 2019) . This suggests that IgG might be related to NMSs in PD patients, but the mechanism remains complex and unclear. The IgG glycosylation profile of PD patients was different from that of the controls, and the capacity for the IgG to inhibit Fcγ-RIIIa binding might decrease, leading to increased antibody-dependent cell cytotoxicity and a state of low-grade inflammation in PD patients (Russell et al., 2017) . Moreover, IgG from patients with PD can induce dopaminergic neuron injury following stereotaxic injection into rat SN (He et al., 2002) . However, although intravenous immunoglobulin (IVIG) does not prevent α-synuclein aggregation, it still may reduce α-synuclein neurotoxicity through an unknown mechanism (Smith et al., 2012) . Further research is needed to explore the role of serum IgG in the pathogenesis of PD.
Limitations of this study include a short mean course of disease of approximately 5 years and no study reported follow-up on the patients. Further comprehensive studies with longer follow-up durations should be conducted to validate the findings of this study.
CONCLUSION
This study profiled the peripheral humoral immune response in patients with PD and revealed that serum C3 and IgG might be correlated with the NMSs of PD.
